MedTrace Logo

PET [89Zr]DFO-starPEG in Solid Tumors

NCT06894745 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-07-22

No results posted yet for this study

Summary

This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.

Conditions

Interventions

DRUG

89-zr-dfo-star polyethylene glycol (StarPEG)

Given intravenously (IV)

PROCEDURE

Whole Body Positron Emission Tomography (PET)

Imaging procedure

PROCEDURE

Specimen Collection

Urine and blood specimens will be collected for correlative studies

Sponsors & Collaborators

  • ProLynx LLC

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • Robert Flavell, MD, PhD

    lead OTHER

Principal Investigators

  • Robert Flavell, MD, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06894745 on ClinicalTrials.gov